Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Pharmacokinetics of DCBCI0901 in Patients With Advanced Solid Tumor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult male or female patients, age at consent ≥20 years.~2. Patients with pathologically or cytologically confirmed advanced solid tumor(s), failed to respond to standard therapy.~3. Measurable or non measurable disease on imaging by RECIST v1.1.~4. ECOG PS of 0 and 1.~5. Any acute or chronic clinically significant adverse effects of prior chemotherapy have resolved to ≤Grade 1 as determined by the CTCAE v4.0 criteria.~6. Life expectancy ≥12 weeks.~7. No prior cytotoxic chemotherapy, radiation therapy, or immunosuppressive therapy within 4 weeks of starting study treatment.~8. Have not participated in any other investigational trials within 28 days before commencing the study treatment.~9. Eligible organ function~10. Patients with primary liver cancer or hepatic metastasis are eligible to enroll,~11. No active infections or unstable angina, or myocardial infarction within 6 months or coexisting medical problems of sufficient severity to limit compliance in the study.~12. No known concomitant genetic or acquired immunosuppressive diseases~13. No history of alcoholism, drug addiction or psychotic disorders.~14. Negative urine β human chorionic gonadotropin test in women of childbearing potential at Screening.~15. Patients who agree that they or their partner(s), if WOCBP, will practice contraception during the study period~16. If there is a history of brain metastases or spinal cord compression treated with radiation and/or surgery, the therapy must have occurred at least 3 months prior to enrollment and the metastatic disease must have been stable since completion.~17. Patients who are fully informed about the content of the study by the Investigator using the specified written consent form~Exclusion Criteria:~1. Uncontrolled systemic infection at Screening, including patients who are positive and at risk~2. Severe or poorly controlled systemic illnesses that may affect the conduct or results of the study.~3. Presence of ≥Grade 2 non hematological AEs at Screening for which a causal relationship with prior therapies cannot be ruled out~4. Long QT syndrome,~5. Symptoms of peripheral neuropathy.~6. Concomitant treatment with, or anticipated use of, pharmaceutical, non pharmaceutical agents which are known potent inhibitors for Cytochrome P450~7. Patients on traditional Chinese medicine (TCM) or plan to take TCM.~8. Women who are nursing or pregnant during the study period.~9. Patients who have a history of hypersensitivity to mTOR inhibitors or any of the ingredients.~10. Patients who cannot communicate reliably with the Investigator.~11. Patients who are unlikely to cooperate with the requirements of the study.~12. Other cases judged by the Investigator to be ineligible for participation in the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- DCBCI0901 (Type: EXPERIMENTAL): DCBCI0901 7.5mg/m2, iv infusion for day 1-day 5 and day 15-day 20

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues